Home > Cardiology > ESC 2021 > Finerenone favourable for diabetic patients with chronic kidney disease

Finerenone favourable for diabetic patients with chronic kidney disease

Presented By
Prof. Bertram Pitt, University of Michigan School of Medicine, USA
Conference
ESC 2021
Trial
FIGARO-DKD
The multinational  FIGARO-DKD trial investigated the effect of mineralocorticoid receptor antagonist treatment on cardiovascular outcomes in patients with mild-to-moderate kidney disease and type 2 diabetes (T2D). Finerenone decreased cardiovascular morbidity and mortality and kidney disease progression [1,2]. The risk of hospitalisation for heart failure and cardiovascular death is markedly increased in patients with chronic kidney disease (CKD) and T2D. The FIGARO-DKD trial (NCT02545049) investigated whether finerenone would reduce the cardiovascular risk in these patients. After a run-in phase of 4–16 weeks, during which the renin-angiotensin system inhibition therapy of the patients was optimised, the study randomised 7,437 adults to finerenone 10 mg/20 mg daily or placebo. Among the inclusion criteria was an eGFR ≥25 mLl/min/1.73 m², urine albumin to creatinin...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on